What Has Been the Progress and Growth of the Acute Renal Failure ARF Market in Recent Years?
The acute renal failure arf market has seen considerable growth due to a variety of factors.
• The market size for acute renal failure (ARF) has experienced noticeable growth in the past years. Expanding from $6.09 billion in 2024, it is anticipated to reach $6.62 billion in 2025, showing a compound annual growth rate (CAGR) of 8.6%.
Factors contributing to this growth during the historical period include an increase in the elderly population, higher incidences of sepsis, enhanced diagnostic facilities, governmental healthcare policies, and escalating cases of nephrotoxic medication.
How Does the Forecast Look for the Acute Renal Failure ARF Market?
The acute renal failure arf market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming few years, the acute renal failure (ARF) is projected to experience robust growth of its market size, expanding to a whopping $9.09 billion by 2029 at a compound annual growth rate (CAGR) of 8.3%.
The accelerated growth anticipated in the forecast period could be a result of factors like amplification of home-based dialysis solutions, evolving markets, the creation of renal biomarkers, research and development in the realm of new therapeutic drugs, and a swelling demand for non-invasive diagnostics. In addition, other important elements predicted to shape the market in the forecast period incorporate innovations in continuous renal replacement therapy (CRRT), leaps in 3d bioprinting of renal tissue, use of wearable biosensors, advancements in next-generation dialysis machines, and evolution of nanotechnology-driven drug delivery.
What Are The Leading Drivers Of Growth In The Acute Renal Failure ARF Market?
The growth of the acute renal failure (ARF) market is projected to be fueled by the increasing instances of chronic kidney diseases. Chronic kidney disease (CKD), a condition where the kidneys become incapable of efficient blood filtration, is on the rise due to the escalating prevalence of diabetes, hypertension, obesity, aging demographics, and lifestyle-related factors around the globe. Acute renal failure, characterized by an abrupt decline in kidney functionality, may significantly worsen or trigger chronic kidney disease through permanent harm to the kidney tissues, decrease in filtration efficacy, and increase the likelihood of a progressive, permanent kidney dysfunction if left uncontrolled. As per a June 2023 report by Kidney Research UK, a non-profit organization based in UK, about 7.2 million people or over 10% inhabitants of the UK are currently affected by chronic kidney disease. Out of these, 3.25 million are battling with the advanced stages, while around 3.9 million are in the early stages. The number of individuals afflicted by chronic kidney disease is expected to climb to 7.61 million by 2033. Hence, the escalating instances of chronic kidney diseases are stimulating the growth of the acute renal failure (ARF) market.
How Are The Segments Defined Within The Global Acute Renal Failure ARF Market?
The acute renal failure (ARF) market covered in this report is segmented –
1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure
2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Others Drugs
3) By Route of Administration: Oral, Intravenous
4) By Diagnosis: Computed Tomography (CT) Scan, Kidney Biopsy, Ultrasound
5) By End-Users: Clinics, Hospitals, Home Healthcare, Others End-Users
Subsegments:
1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis
2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis
3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones
Pre-Book The Acute Renal Failure ARF Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Acute Renal Failure ARF Market?
Prominent firms within the acute renal failure (ARF) market are striving to obtain regulatory clearances for drugs to amplify their exposure and fortify their dominance in the arena of severe acute kidney injury (AKI) management. Such approvals are formal consents granted by governmental or regulatory agencies for the public use and advertising of medical treatments, drugs, or devices. For instance, CalciMedica., an American clinical-stage biopharmaceutical firm, achieved FDA clearance for an IND application for Phase 2 trial of Auxora in February 2024. This was to assess Auxora's potential in managing severe acute kidney injury (AKI) linked to acute hypoxemic respiratory failure (AHRF), an ailment with a substantial mortality rate. The KOURAGE trial, a randomized, double-blind, placebo-controlled study, intends to enroll about 150 patients afflicted with stage 2 and 3 acute kidney injury (AKI) and acute hypoxemic respiratory failure (AHRF). The efficacy of Auxora will be judged over five daily doses by determining the number of days patients survive without requiring ventilators or dialysis up to 30 days after treatment.
Who Are the Key Players In The Acute Renal Failure ARF Market?
Major companies operating in the acute renal failure (ARF) market are:
• Pfizer Inc.
• Novartis AG
• LG Chem Ltd.
• Medtronic plc
• Fresenius Medical Care AG & Co. KGaA
• Asahi Kasei Corporation
• Baxter International Inc.
• Astellas Pharma Inc.
• Syensqo
• Dr. Reddy's Laboratories Limited
• Zydus Lifesciences Limited
• NIKKISO Co.. Ltd.
• Quark Pharmaceuticals Inc.
• NIPRO Corporation
• Alloksys Life Sciences B.V.
• AM-Pharma B.V.
• Sentien Biotechnologies
• MediBeacon LLC
• Angion Biomedica Corp.
• Atox Bio Ltd.
What Is The Most Dominant Region In The Acute Renal Failure ARF Market?
North America was the largest region in the acute renal failure (ARF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (ARF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
